This concept was proven clinically in a phase Ib trial combining vermurafenib (a BRAF inhibitor) with cetuximab (an EGFR inhibitor) and irinotecan for BRAF V600E mutated CRC [14]. Here, BRAF is linked to colorectal carcinoma.